USA - NYSE:RMD - US7611521078 - Common Stock
The current stock price of RMD is 246.88 USD. In the past month the price decreased by -11.38%. In the past year, price increased by 1.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B | ||
| STE | STERIS PLC | 24.71 | 23.21B | ||
| DXCM | DEXCOM INC | 31.3 | 22.83B |
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,600 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
RESMED INC
9001 Spectrum Center Blvd
San Diego CALIFORNIA 92123 US
CEO: MichaelJ.Farrell
Employees: 9980
Phone: 18587462400
ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,600 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.
The current stock price of RMD is 246.88 USD. The price decreased by -2.13% in the last trading session.
RESMED INC (RMD) has a dividend yield of 0.97%. The yearly dividend amount is currently 2.12.
RMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
RMD stock is listed on the New York Stock Exchange, Inc. exchange.
RESMED INC (RMD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
RESMED INC (RMD) will report earnings on 2026-01-28.
ChartMill assigns a fundamental rating of 8 / 10 to RMD. Both the health and profitability get an excellent rating, making RMD a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months RMD reported a non-GAAP Earnings per Share(EPS) of 9.9. The EPS increased by 19.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.22% | ||
| ROA | 17.14% | ||
| ROE | 23.47% | ||
| Debt/Equity | 0.11 |
25 analysts have analysed RMD and the average price target is 301.14 USD. This implies a price increase of 21.98% is expected in the next year compared to the current price of 246.88.
For the next year, analysts expect an EPS growth of 14.64% and a revenue growth 9.1% for RMD